Triomics
It builds oncology-specific AI software to help cancer centers apply artificial intelligence in cancer care workflows.
Overview
Triomics develops oncology-specific AI for cancer centers, focusing on software tailored to the clinical and operational complexity of cancer care. Its target market is hospitals and cancer centers seeking AI systems built for oncology rather than generic healthcare workflows. The company’s positioning centers on a domain-specific approach to cancer care AI. Triomics raised a $22 million Series B on May 27, 2026, bringing disclosed funding to $22 million across one round.
Funding History
Triomics nabs $22M to bring oncology-specific AI to cancer centers
Frequently Asked Questions
- How much funding does AI Funding track for Triomics?
- AI Funding tracks $22M for Triomics across 1 funding round in this database.
- Who are Triomics's investors?
- Triomics's investors include Lightspeed Venture Partners, Y Combinator, Nexus Venture Partners, Battery Ventures.
- What does Triomics do?
- Triomics develops oncology-specific AI for cancer centers, focusing on software tailored to the clinical and operational complexity of cancer care. Its target market is hospitals and cancer centers seeking AI systems built for oncology rather than generic healthcare workflows. The company’s positioning centers on a domain-specific approach to cancer care AI. Triomics raised a $22 million Series B on May 27, 2026, bringing disclosed funding to $22 million across one round.
- Where is Triomics headquartered?
- Triomics is headquartered in San Francisco, USA.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.